Articles tagged "Mycophenolate mofetil"

2022 American Transplant Congress
Assessing Proportion of Days Covered (PDC) of Mycophenolate (MCP) Prescriptions in Post Kidney Transplant (KT) Recipients as a Predictor of Clinical Outcomes
K. Sandlin¹, T. Sam¹, N. Wilson¹, A. Yango², B. Fischbach³, A. Dao¹
¹Pharmacy, Baylor University Medical Center, Dallas, TX, ²Baylor All Saints Medical Center, Dallas Nephrology Associates, Fort Worth, TX, ³Baylor University Medical Center, Dallas Nephrology Associates, Dallas, TX
*Purpose: Nonadherence to medications following KT is a risk factor for adverse outcomes. PDC is an objective measure of adherence obtained through retail prescription records…
2022 American Transplant Congress
Reduced Dose Mycophenolate Does Not Increase the Risk of Rejection Following Renal Transplantation
L. Bowman¹, A. Webb¹, S. Desai², D. Patino³, V. Subramanian⁴, S. Mohammed⁵, M. Gosselin⁶, K. Robichaux⁵, J. Buggs⁴, A. Kumar⁷
¹Transplant Pharmacy, Tampa General Hospital, Tampa, FL, ²Western University of Osteopathic Medicine, Pomoma, CA, ³Michigan State University College of Human Medicine, Lansing, MI, ⁴Transplant Surgery, Tampa General Hospital, Tampa, FL, ⁵University of South Florida, Tampa, FL, ⁶University of Tampa, Tampa, FL, ⁷Morsani College of Medicine, University of South Florida, Tampa, FL
*Purpose: Mycophenolic acid (MPA) exposure correlates inversely with the risk of acute rejection; however, evidence also suggests that systemic MPA exposure also determines the extent…
2021 American Transplant Congress
ABCC2 Haplotypes Associations to Mycophenolic Acid Pharmacokinetics in Stable Renal Transplant Recipients
K. Tornatore¹, D. Brazeau², C. Meaney³, J. Consiglio⁴, A. Gundroo⁵, S. Chang⁶, G. Wilding⁴, L. Cooper³
¹Pharmacy Practice, School of Pharmacy; University at Buffalo- SUNY, Buffalo, NY, ²Pharmacy Practice, Marshall University, Huntington, WV, ³Pharmacy Practice, School of Pharmacy; University at Buffalo, Buffalo, NY, ⁴Biostatistics, School of Public Health; University at Buffalo, Buffalo, NY, ⁵Medicine, School of Medicine; Ohio State University, Columbus, OH, ⁶Medicine, School of Medicine; University at Buffalo, Buffalo, NY
*Purpose: Mycophenolic acid (MPA), exhibits interpatient pharmacokinetic (PK) variability attributed to enterohepatic circulation of the glucuronide metabolite (MPAG) to MPA. This is mediated by multidrug…
2021 American Transplant Congress
Dietary Intake and Mycophenolate Mofetil-related Diarrhea Following Kidney Transplantation
G. Onyeaghala¹, L. Teigen², B. Guo², Y. Doronin¹, M. Al-Kofahi², B. Wu², W. Guan², C. Staley², S. Riad², A. Matas², R. Remmel², W. Oetting², C. Dorr¹, P. Jacobson², A. Israni¹
¹Nephrology, Hennepin Healthcare Research Institute, Minneapolis, MN, ²University of Minnesota, Minneapolis, MN
*Purpose: The treatment of Mycophenolate mofetil (MMF) related diarrhea in kidney transplants recipients involves providing lower MMF doses more frequently to maintain the same daily…
2021 American Transplant Congress
Tolerability of Mycophenolate Mofetil in Elderly Kidney Transplant Recipients: A Retrospective Cohort Study
S. Witek¹, G. Malat², D. Sawinski², C. Sammons², C. LaFratte¹, A. Forte¹, R. Samudralwar¹, S. Lyle¹, J. Rashid¹, J. Trofe-Clark²
¹Dept of Pharmacy, Hospital of the Univ of Pennsylvania, Philadelphia, PA, ²Penn Transplant Institute, Hospital of the Univ of Pennsylvania, Philadelphia, PA
*Purpose: Optimal immunosuppression in elderly kidney transplant recipients (KTRs) is not well-defined, with MMF being poorly tolerated at standard doses. This study aims to compare…
2020 American Transplant Congress
A Novel Formula to Determine Optimal Immunosuppression in Renal Transplant Recipients Treated with Tacrolimus and Mycophenolate Mofetil: Towards Individualized Immunosuppression
O. Pankewycz¹, M. Laftavi¹, E. Onan², D. Rucker¹, D. Wang¹, K. Bhuta¹, R. Gruessner³, A. Gruessner³
¹SUNY, Upstate Medical University, Syracuse, NY, ²Cukurova University, Adana, Turkey, ³SUNY, Downstate Medical University, New York, NY
*Purpose: Tacrolimus (TAC) and mycophenolic acid (MPA) remain the most commonly used drug combination for kidney transplant immunosuppression. Adequate drug dosing is challenging due to…
2020 American Transplant Congress
The Role of mTOR Inhibitors on Cardiovascular Aging in Renal Transplanted Patients with Chronic Graft Dysfunction
G. Castellano¹, B. Infante¹, P. Pontrelli¹, R. Franzin¹, F. Rascio¹, C. Prisciandaro², L. Gesualdo¹, N. Coviello³, G. Grandaliano³, G. Stallone³
¹Emergency and Organ Transplantation, University of Bari, Bari, Italy, ²University of Foggia, Foggia, Italy, ³Emergency and Organ Transplantation, University of Foggia, Foggia, Italy
*Purpose: Chronic Kidney Disease (CKD) is strongly associated with increased circulatory complications that can lead to accelerated cardiovascular aging. During CKD, persistent oxidative stress triggered…
2020 American Transplant Congress
Low Mycophenolic Acid Levels are Associated with More Inflammation on 1 Year Protocol Biopsies and Lower Graft Survival in Kidney Transplant Recipients
J. Huskey, G. Mour, M. Ryan, S. Nair, M. Smith, R. Heilman
Mayo Clinic Arizona, Phoenix, AZ
*Purpose: Data is limited on the association of Mycophenolic Acid (MPA) concentration on protocol kidney transplant biopsies. Our aim is to compare clinical outcomes and…
2020 American Transplant Congress
Outcomes Associated with Mycophenolate Weight-Based Dosing in Varying Immunologic Risk Kidney Transplant Recipients
A. A. Al-Bahou, A. R. Webb, M. Bloxam, L. J. Bowman Anger, R. S. Baliga, A. J. Brueckner
Tampa General Hospital, Tampa, FL
*Purpose: Mycophenolate acid (MPA) is traditionally dosed in kidney transplant recipients (KTR) using the FDA-approved fixed dosing which is irrespective of patient-specific variables such as…
2020 American Transplant Congress
Conversion to Sirolimus to Prevent Recurrent Cytomegalovirus Infection/Disease: A Prospective and Randomized Trial
L. Almeida Viana, M. Pontello Cristelli, G. Basso, D. Wagner Castro Lima Santos, M. Taver Costa Dantas, Y. Cardoso Dreige, L. Damasceno, M. Rika Nakamura, H. Tedesco-Silva, J. Medina-Pestana
Hospital do Rim - UNIFESP, São Paulo, Brazil
*Purpose: Recurrent cytomegalovirus (CMV) infection occurs in 30-35% of kidney transplant recipients after completion of treatment and/or preemptive therapy. There is no consensus on the…